Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System offers a new potential treatment by using sound pressure waves to treat arterial calcium blockages
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
Prithwish has close to 28 years of experience in a Commercial role
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
The company has reported total income of Rs. 1,693.15 crores during the period ended September 30, 2024
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Subscribe To Our Newsletter & Stay Updated
